Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited,
with the currently approved all‐oral regimens requiring 24‐week treatment and the addition …

Background: The hepatitis C pandemic has been systematically studied and characterized
in North America and Europe, but this important public health problem has not received …

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced
liver disease, are a challenging population in urgent need of optimally effective therapies …

Hepatitis C virus (HCV) is endemic in Pakistan and its burden is expected to increase in
coming decades owing mainly to widespread use of unsafe medical procedures. The …

In Pakistan more than 10 million people are living with Hepatitis C virus (HCV), with high
morbidity and mortality. This article reviews the prevalence, genotypes and factors …

Hepatitis C virus (HCV) causes acute and chronic hepatitis which can eventually lead to
permanent liver damage, hepatocellular carcinoma and death. Currently, there is no vaccine …

Hepatitis C virus (HCV) infection is a major public health concern, and almost two million
people are infected per year globally. This is occurred by the diverse spectrum of viral …

Background and aim Phylogenetic analysis has led to the classification of hepatitis C virus
(HCV) into 1-6 major genotypes. HCV genotypes have different biological properties, clinical …

Hepatitis C (HCV) is the disease that has affected around 200 million people globally. HCV
is a life threatening human pathogen, not only because of its high prevalence and worldwide …

Background Over the past several years, hepatitis C therapy has been pegylated interferon
and ribavirin based. Although protease inhibitor‐based therapy has enhanced response …